Startseite Crystal structure of 4-(2-ammonioethyl)morpholin-4-ium dichloride monohydrate, C6H18Cl2N2O2
Artikel Open Access

Crystal structure of 4-(2-ammonioethyl)morpholin-4-ium dichloride monohydrate, C6H18Cl2N2O2

  • Mostafa M. Ghorab EMAIL logo , Mansour S. Alsaid und Hazem A. Ghabbour
Veröffentlicht/Copyright: 10. April 2017

Abstract

C6H18Cl2N2O2, triclinic, P1̅ (no. 2), a = 7.9597(11) Å, b = 9.1223(13) Å, c = 9.2893(12) Å, α = 118.575(3)°, β = 106.507(4)°, γ = 97.120(4)°, V = 540.21(13) Å3, Z = 2, Rgt(F) = 0.0470, wRref(F2) = 0.1156, T = 293 K.

CCDC no.:: 1511400

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Yellow platelet
Size:0.41 × 0.19 × 0.07 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:5.7 cm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
2θmax, completeness:55°, >99%
N(hkl)measured, N(hkl)unique, Rint:16934, 2490, 0.092
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1686
N(param)refined:133
Programs:SHELX [1], Bruker programs [2]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Cl21.16939(9)0.83443(9)0.70934(9)0.0395(2)
Cl10.20301(9)0.47063(9)0.15955(9)0.0427(2)
O10.6678(3)1.0584(2)0.7391(2)0.0409(5)
N10.7528(3)0.7534(2)0.5189(3)0.0228(4)
O2W0.4038(3)0.2377(3)−0.0464(3)0.0530(6)
N20.7840(4)0.3886(3)0.1084(3)0.0346(5)
C50.7040(3)0.5746(3)0.3578(3)0.0287(5)
H5A0.57670.53980.27880.034*
H5B0.71550.49130.39390.034*
C10.7347(4)0.8929(3)0.4799(3)0.0309(6)
H1A0.60920.86270.39970.037*
H1B0.81590.90140.42180.037*
C60.8265(4)0.5690(3)0.2587(3)0.0317(6)
H6A0.80820.64530.21430.038*
H6B0.95450.61140.33940.038*
C30.6880(4)0.9316(3)0.7835(3)0.0413(7)
H3A0.60990.92880.84620.050*
H3B0.81470.96470.86300.050*
C40.6378(4)0.7518(3)0.6207(3)0.0329(6)
H4A0.65690.66900.65620.039*
H4B0.50850.71430.54510.039*
C20.7838(4)1.0664(3)0.6506(4)0.0409(7)
H2A0.91091.09840.72840.049*
H2B0.77211.15640.62430.049*
H1N10.865(4)0.778(3)0.581(3)0.035(8)*
H2OW0.336(5)0.283(4)0.007(4)0.061(11)*
H2N20.815(5)0.323(4)0.146(4)0.063(11)*
H1OW0.350(5)0.134(4)−0.102(5)0.059(11)*
H3N20.846(5)0.395(5)0.049(5)0.080(13)*
H1N20.667(5)0.345(4)0.037(4)0.062(11)*

Source of material

2-Morpholinoethanamine (1.30 g, 0.01 mol) was added to ethanol (15 mL) containing a few drops diluted hydrochloric acid. The mixture was heated under reflux for 15 min. The corresponding 4-((2-ammonioethyl)morpholin-4-ium dichloride monohydrate was obtained in good yield. Yield%: 81. M.p. = 122.2 °C. 1H-NMR: 1.0 [m, 4H, CH2—NH—CH2 cyclo], 3.6 [t, 2H, CH2—NH3], 3.9 [m, 4H, CH2—O—CH2 cyclo], 4.1 [t, 2H, NH—CH2], 7.2 [s, 4H, NH3 + NH]. 13C-NMR: 36.8 (CH2—NH3), 50.1(2) (CH2—NH—CH2), 54.4 (CH2—NH), 64.7(2) (CH2—O—CH2). MS (EI, 70 EV): m/z = 130 [M+]. Elemental Anal. Calcd. for C6H18Cl2N2O2 (221.13): C 32.59; H 8.20; N 12.67. Found: C 32.29; H 8.48; N 12.83.

Experimental details

All hydrogen atoms were identified in difference Fourier synthesis. The hydrogen atoms of the CH2 groups were positioned geometrically and allowed to ride on their parent atoms, with Uiso(H) = 1.2Ueq(C). Nitrogen bound hydrogen atoms as well as those of the water molecule were located from the electron density map and refined freely.

Comment

Attributable to the massive applicability of morpholine, it is coveted to attain widespread and efficacious procedures for their construction. Morpholine has been reported to show anticancer activity [3], and extra biological activities [4], [5], [6], [7]. In perseverance of our curiosity in the synthesis of brilliant heterocyclic derivatives [8], [9], [10], [11], we synthesized the title compound.

The crystal structure of the title compound contains one dication and two anions in the asymmetric unit together with one molecule of water. In the crystal structure, the molecules are stabilized by some intermolecular hydrogen bonds, of which Cl2, Cl1 and O1 act as hydrogen bond acceptors and N2, O2W, C1 and C4 work as hydrogen bond donors. The distance of the interactions between N2—H2N2⋅⋅⋅Cl2i, O2W—H1OW⋅⋅⋅Cl2ii, N2—H3N2⋅⋅⋅Cl1iii, N2—H3N2⋅⋅⋅Cl1iv, C1—H1A⋅⋅⋅O1v and C4—H4A⋅⋅⋅Cl1vi are 2.38(4), 2.37(4), 2.61(4), 2.71(5), 2.59, and 2.67 Å, respectively and the angles are 162(4), 173(4), 125(3), 129(4), 153 and 162°, respectively.

Acknowledgement

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding of this research through the Research Group Project no. RGP-302.

References

1 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

2 Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA, (2009).Suche in Google Scholar

3 Nura, S. G.; Pouya, H. D.: Synthesis, characterization and anticancer studies of some morpholine derived Schiff bases and their metal complexes. J. App. Pharm. Sci. 4 (2014) 75–80.10.7324/JAPS.2014.401014Suche in Google Scholar

4 Mohammed, A.; Bushra, B. A.; Zabiulla, M. S. V.; Shaukath, A. K.: Piperazine and morpholine: Synthetic preview and pharmaceutical applications. J. Chem. Pharm. Research 7 (2015) 281–301.Suche in Google Scholar

5 Jakubowska, J.; Wasowska-Lukawska, M.; Czyz, M.: STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Eur. J. Pharmacol. 596 (2008) 41–49.10.1016/j.ejphar.2008.08.021Suche in Google Scholar PubMed

6 Hahn, V.; Mikolasch, A.; Wende, K.; Bartrow, H.; Lindequist, U.; Schauer, F.: Synthesis of model morpholine derivatives with biological activities by laccase-catalysed reactions. Biotechnol. Appl. Biochem. 54 (2009) 187–195.10.1042/BA20090219Suche in Google Scholar PubMed

7 Panneerselvam, P.; Nair, R. R.; Vijayalakshmi, G.; Subramanian, E. H.; Sridhar, S. K.: Synthesis of schiff bases of 4-(4-aminophenyl)-morpholine as potential antimicrobial agents. Eur. J Med. Chem. 40 (2005) 225–229.10.1016/j.ejmech.2004.09.003Suche in Google Scholar PubMed

8 Ghorab, M. M.; Alsaid, M. S.; Al-Ansary, G. H.; Abdel-Latif, G. A.; Abou El Ella, D. A.: Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers. Eur. J. Med. Chem. 124 (2016) 946–958.10.1016/j.ejmech.2016.10.020Suche in Google Scholar PubMed

9 Ghorab, M. M.; Alsaid, M. S.; Higgins, M.; Dinkova-Kostova, A. T.; Shahat, A. A.; Elghazawy, N. H.; Arafa, R. K.: Synthesis, molecular modeling and NAD(P)H:quinone oxidoreductase 1 inducer activity of novel 2-phenylquinazolin-4-amine derivatives. J. Enzy. Inhib. Med. Chem. 31 (2016) 1612–1618.10.3109/14756366.2016.1158714Suche in Google Scholar PubMed

10 Ghorab, M. M.; Alsaid, M. S.; El-Gazzar, M. G.; Higgins, M.; Dinkova-Kostova, A. T.; Shahat, A. A.: NAD(P)H: quinone oxidoreductase 1 inducer activity of novel 4-aminoquinazoline derivatives. J. Enzy. Inhib. Med. Chem. 31 (2016) 1369–1374.10.3109/14756366.2015.1135913Suche in Google Scholar PubMed

11 Ghorab, M. M.; Alsaid, M. S.; El-Gaby, M. S. A.; Safwat, N. A.; Elaasser, M. M.; Soliman, A. M.: Biological evaluation of some new N-(2,6-dimethoxypyrimidinyl) thioureido benzenesulfonamide derivatives as potential antimicrobial and anticancer agents. Eur. J. Med. Chem. 124 (2016) 299–310.10.1016/j.ejmech.2016.08.060Suche in Google Scholar PubMed

Received: 2016-10-30
Accepted: 2017-3-20
Published Online: 2017-4-10
Published in Print: 2017-5-24

©2017 Mostafa M. Ghorab et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2,5-diiodo-4-nitro-1H-imidazole hemihydrate, C6H4I4N6O5
  3. Crystal structure of catena-poly[μ2-2,2′-(1,3-phenylene)diacetato-κ4O,O′:O′′,O′′′)-(μ2-1,6-bis(2-methyl-1H-benzo[d]imidazol-1-yl)hexane-κ2N:N′)cadmium(II)], C32H34CdN4O4
  4. Crystal structure of poly[aqua-(2,2′-bipyridine-κN,N′)-(μ4-5,5′-(hexane-1,6-diyl)-bis(oxy)diisophthalato κ8O1,O2:O3,O4:O5,O6:O7,O8)manganese(II)], C21H21MnN2O7
  5. Crystal structure of poly-[(μ2-((1,3-bis(benzimidazol-1-yl)propane-κ2N:N′)(μ2-4-tert-butyl-phthalato-κ2O:O′)cobalt(II)] monohydrate, C29H30CoN4O5
  6. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-5-(oxo-5,6,7,8-tetrahydro-4H-chromene)-3-carbonitrile – ethanol (1/1), C21H26N2O6
  7. Crystal structure of ethyl 1-benzyl-5-phenyl-1H-pyrazole-3-carboxylate, C19H18N2O2
  8. Crystal structure of 2-(1-benzyl-3-phenyl-1H-pyrazol-5-yl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole, C25H19N5O3S
  9. Structure and photochromism of 1,2-bis[2-methyl-5-(2-chlorophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C27H16Cl2F6S2
  10. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-4-ylmethylene)aniline, C18H22N2
  11. Crystal structure of (E)-2,4-dibromo-6-(((4-methyl-2-nitrophenyl)imino) methyl)phenol, C10H14Br2N2O3
  12. Crystal structure of (bis(2,2′-bipyridine-κ2N,N′))-(3,5-dinitrosalicylato-κ2O,O′)nickel(II), C27H18N6NiO7
  13. Crystal structure of 1-(diethoxy phosphonomethyl) 2-benzoyl-3-chloro-2-cyclohexen-1-ol, C18H24ClO5P
  14. Crystal structure of tetraaqua-bis(1,3-benzimidazol-3-ium-1,3-diacetato-κO)copper(II) hemihydrate, C22H27CuN4O12.50
  15. Crystal structure of 1α,11-dihydroxyeremophil-9-en-8-one, C15H24O3
  16. Crystal structure of 1-ferrocenylsulfonyl-1H-imidazo[4,5-b]pyridine, C16H13FeN3O2S
  17. Crystal structure of bis(μ2-azido-κ2N:N)-dichlorido-bis(μ2-2-(pyridin-2-yl)ethan-1-ol-κ2O,N)dicopper(II), C14H18Cl2Cu2N8O2
  18. Crystal structure of (5,15-cis-bis(2-hydroxy-1-naphthyl)-10-phenyl-20-(4-hydroxyphenyl)-porphyrinato)-(pyridine)-zinc(ii) pyridine solvate, C67H47N7O3Zn
  19. Crystal structure of (μ2-[2,2′-bis(diphenylphosphino)-1,1′-binaphthalene oxide-κ2O,P])-iodido copper(I), C44H32CuIOP2
  20. Crystal structure of 6,8-diphenyl-2-(4-fluorophenyl)-2,3-dihydroquinolin-4(3H)-one, C27H20FNO
  21. Crystal structure of 5,11,17,23-tetra(tert-butyl)-25,26,27,28-tetrahexoxycalix[4]arene, C68H104O4
  22. Crystal structure of N,N′–bis(pyridin-4-ylmethyl)pyrazine-2,3-dicarboxamide dihydrate, C18H20N6O4
  23. Crystal structure of a diaqua-bis(3,5-di(1H-imidazol-1-yl)pyridine-κN)-bis(2-(4-carboxy-phenyl)acetato-κO]manganese(II), C40H36MnN10O10
  24. Crystal structure of 4-(4-hydroxy-3-methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid methyl ester, C21H25NO5
  25. Crystal structure of (E)-4,4′-(ethene-1,2-diyl)bis(3-nitrobenzoic acid) 1.5 hydrate, C16H13N2O9.5
  26. Crystal structure of (E)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-((4-fluorophenyl)diazenyl)-4-methylthiazole, C23H17F2N5OS
  27. Crystal structure of the co-crystalline adduct 4-((4,4-dimethyl-2,6-dioxocyclohexylidene)methylamino)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide - acetic acid (1/1), C21H24N4O4S ⋅ C2H4O2
  28. Synthesis and crystal structure of 2-((5-chlorobenzo[c][1,2,5]thiadiazol-4-yl)amino)-4,5-dihydro-1H-imidazol-3-ium tetraphenylborate, C33H29BClN5S
  29. Crystal structure of (4-chlorophenyl)(3-ferrocenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methanone, C21H14ClF3FeN2O
  30. Crystal structure of (S)-benzyl 3-(benzylcarba-moyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate, C25H24N2O3
  31. Crystal structure of 5-acetyl-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one, C15H17FN2O4
  32. Crystal structure of 2-(4-fluorophenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C19H16FIN2
  33. Crystal structure of methyl 1H-indole-2-carboxylate, C10H9NO2
  34. Crystal structure of 2,3-diphenyl-1-[(dipropylamino)acetyl]-1,3-diazaspiro[4.5]decan-4-one, C28H37N3O2
  35. Crystal structure of 1-(2H-1,3-benzodioxol-5-yl)-3-(1H-imidazol-1-yl)propan-1-one, C13H12N2O3
  36. Crystal structure of 2,9-dibromo-1,10-phenanthroline, C12H6Br2N2
  37. Crystal structure of 3-(adamantan-1-yl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5(4H)-thione, C18H20FN3S
  38. Crystal structure of trans-bis((E)-7-oxo-4-(phenyldiazenyl)cyclohepta-1,3,5-trien-1-olato)-κ2O,O′)-bis(pyridine-κN)cobalt(II), C36H28CoN6O4
  39. Crystal structure of 2-(4-methyl-3-phenylthiazol-2(3H)-ylidene)malononitrile, C13H9N3S
  40. Crystal structure of (Z)-3-(adamantan-1-yl)-1-(3-chlorophenyl)-S-benzylisothiourea, C24H27ClN2S
  41. Crystal structure of chlorido{[3-(η5-cyclopenta-dienyl)-2,2,3-trimethyl-1-phenylbutylidene] azanido-κN}[η2(N,O)-N,N-dimethylhydroxylaminato]titanium(IV), C20H27ClN2OTi
  42. Crystal Structure of 1,1′-dimethyl-[4,4′-bipyridine]-1,1′-diium tetrachloridozincate(II), C12H14Cl4N2Zn
  43. Crystal structure of 5-nitro-2-(pyrrolidin-1-yl)benzaldehyde, C11H12N2O3
  44. Crystal structure of 2,3-diphenyl-1-(morpholin-4-ylacetyl)-1,3-diazaspiro[4.5]decan-4-one, C26H31N3O3
  45. Crystal structure of 3,3-dimethyl-3,4-dihydro-1H-benzo[c]chromene-1,6(2H)-dione, C15H14O3
  46. Crystal structure of bis(2-(2-hydroxymethyl)pyridine-κ2N,O)-bis(pivalato-κO)nickel(II), C22H32N2NiO6
  47. Crystal structure of (1,10-phenanthroline-κ2N,N′)-bis(1H-pyrazole-3-carboxylato-κ2N,O)manganese(II) trihydrate, C20H20N6O7Mn
  48. The crystal structure of 3-aminopropan-1-aminium iodide, C3H11N2I
  49. Crystal structure of ethyl 1-(4-chlorophenyl)-5-methyl-1H-1,2,3-triazole-4 carboxylate, C12H12ClN3O2
  50. Crystal structure of 4,4′-((1Z,1′Z)-2,2′-(2,5-diethoxy-1,4-phenylene)bis(ethene-2,1-diyl))dipyridine, C24H24N2O2
  51. Crystal structure of (16S)-12,16-epoxy-11,14-dihydroxy-17(15/16)-abeo-3a,18-cyclo-8,11,13-abietatrien-7-one, C20H24O4
  52. Crystal structure of aquadichlorido(2,4,6-tri-2-pyridyl-1,3,5-triazine-κ3N,N′,N′′)nickel(II) monohydrate, C18H16Cl2N6NiO2
  53. Crystal structure of catena-poly[dichlorido-(μ-ethane-1,2-diyl-bis-(pyridyl-4-carboxylate-κN:N′)mercury(II)], C15H14Cl2HgN2O4
  54. Crystal structure of methyl 2-acetamido-5-chlorbenzoate, C10H10ClNO3
  55. Crystal structure of tetrakis(μ2-3,3-dimethylacrylato-κ2O,O′)-bis(2-aminopyrimidine-κN) dicopper(II), C28H38Cu2N6O8
  56. Crystal structure of 3-amino-8-methoxy-1-phenyl-1H-benzo[f]chromene-2-carbonitrile, C21H16N2O2
  57. Crystal structure of 4-(2-ammonioethyl)morpholin-4-ium dichloride monohydrate, C6H18Cl2N2O2
  58. Crystal structure of 1-(3-((5-bromo-2-hydroxybenzylidene)amino)phenyl)ethanone O-benzyl oxime, C22H19BrN2O2
  59. Crystal structure of 2-(4-(dimethylamino)-2-fluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol monohydrate, C15H20FN7O2
  60. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
  61. Crystal structure of 1,2,3,4,5-pentamethyl-1,3-cyclopentadiene, C10H16
Heruntergeladen am 22.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0342/html
Button zum nach oben scrollen